NIH Translational Science Center Gets Expanded Powers In Cures Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
When NCATS was created, industry was wary of allowing Phase III trials; now sponsors embrace it.
You may also be interested in...
Congressional ‘Cures’ Debate Shifts To FDA Funding
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
Clinical Trial Data Release: Be Careful What You Wish For, Industry Exec Says
Some advocates and researchers say that data availability could inform repurposing opportunities for products, but a GSK exec cautions that it could just as easily bring a flood of confusing information.
NIH Drug Repurposing Program Produces Surprise Overlaps
Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.